JP2020198875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020198875A5 JP2020198875A5 JP2020082964A JP2020082964A JP2020198875A5 JP 2020198875 A5 JP2020198875 A5 JP 2020198875A5 JP 2020082964 A JP2020082964 A JP 2020082964A JP 2020082964 A JP2020082964 A JP 2020082964A JP 2020198875 A5 JP2020198875 A5 JP 2020198875A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cancer
- cell
- nucleic acid
- peptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192670P | 2015-07-15 | 2015-07-15 | |
| US62/192,670 | 2015-07-15 | ||
| GBGB1512369.8A GB201512369D0 (en) | 2015-07-15 | 2015-07-15 | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB1512369.8 | 2015-07-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501316A Division JP6862411B2 (ja) | 2015-07-15 | 2016-07-14 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020198875A JP2020198875A (ja) | 2020-12-17 |
| JP2020198875A5 true JP2020198875A5 (2) | 2021-04-22 |
Family
ID=54013984
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501316A Expired - Fee Related JP6862411B2 (ja) | 2015-07-15 | 2016-07-14 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020052558A Expired - Fee Related JP7074367B2 (ja) | 2015-07-15 | 2020-03-24 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020059702A Active JP7239992B2 (ja) | 2015-07-15 | 2020-03-30 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020068264A Expired - Fee Related JP7074369B2 (ja) | 2015-07-15 | 2020-04-06 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020071602A Expired - Fee Related JP7074370B2 (ja) | 2015-07-15 | 2020-04-13 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020074570A Active JP7239993B2 (ja) | 2015-07-15 | 2020-04-20 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020078116A Pending JP2020182458A (ja) | 2015-07-15 | 2020-04-27 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020082964A Pending JP2020198875A (ja) | 2015-07-15 | 2020-05-11 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020086514A Active JP7205919B2 (ja) | 2015-07-15 | 2020-05-18 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020090207A Pending JP2021000078A (ja) | 2015-07-15 | 2020-05-25 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications Before (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501316A Expired - Fee Related JP6862411B2 (ja) | 2015-07-15 | 2016-07-14 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020052558A Expired - Fee Related JP7074367B2 (ja) | 2015-07-15 | 2020-03-24 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020059702A Active JP7239992B2 (ja) | 2015-07-15 | 2020-03-30 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020068264A Expired - Fee Related JP7074369B2 (ja) | 2015-07-15 | 2020-04-06 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020071602A Expired - Fee Related JP7074370B2 (ja) | 2015-07-15 | 2020-04-13 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020074570A Active JP7239993B2 (ja) | 2015-07-15 | 2020-04-20 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020078116A Pending JP2020182458A (ja) | 2015-07-15 | 2020-04-27 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086514A Active JP7205919B2 (ja) | 2015-07-15 | 2020-05-18 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020090207A Pending JP2021000078A (ja) | 2015-07-15 | 2020-05-25 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (36)
| Country | Link |
|---|---|
| US (22) | US9889159B2 (2) |
| EP (2) | EP3705491A1 (2) |
| JP (10) | JP6862411B2 (2) |
| KR (2) | KR20220075451A (2) |
| CN (2) | CN114163501A (2) |
| AU (4) | AU2016293047B9 (2) |
| BR (2) | BR112017028558A2 (2) |
| CA (2) | CA2992506A1 (2) |
| CL (5) | CL2018000124A1 (2) |
| CO (1) | CO2018000252A2 (2) |
| CR (4) | CR20200409A (2) |
| CY (1) | CY1123505T1 (2) |
| DK (1) | DK3322717T3 (2) |
| EA (1) | EA201890027A1 (2) |
| ES (1) | ES2807832T3 (2) |
| GB (1) | GB201512369D0 (2) |
| HR (1) | HRP20201281T1 (2) |
| HU (1) | HUE049937T2 (2) |
| IL (3) | IL308200A (2) |
| LT (1) | LT3322717T (2) |
| MA (3) | MA42441B1 (2) |
| MD (1) | MD3322717T2 (2) |
| ME (1) | ME03808B (2) |
| MX (2) | MX2018000543A (2) |
| MY (1) | MY189596A (2) |
| NZ (1) | NZ739128A (2) |
| PE (2) | PE20180693A1 (2) |
| PH (1) | PH12018500005A1 (2) |
| PL (1) | PL3322717T3 (2) |
| PT (1) | PT3322717T (2) |
| RS (1) | RS60647B1 (2) |
| SG (7) | SG10202100291XA (2) |
| SI (1) | SI3322717T1 (2) |
| UA (1) | UA124875C2 (2) |
| WO (1) | WO2017009400A1 (2) |
| ZA (1) | ZA201800129B (2) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201512369D0 (en) * | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| PH12022551111A1 (en) | 2015-10-05 | 2023-08-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| IL299051A (en) * | 2017-01-27 | 2023-02-01 | Immatics Biotechnologies Gmbh | New peptides and their combinations for immunotherapy against ovarian cancer and other cancers |
| EA201991444A1 (ru) | 2017-01-27 | 2019-12-30 | Имматикс Байотекнолоджиз Гмбх | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака |
| MA47367B1 (fr) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| KR20260039788A (ko) | 2017-10-10 | 2026-03-20 | 시애틀 프로젝트 코포레이션 | 핫스팟을 이용한 신생항원 동정 |
| CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| EP3749753B1 (en) | 2018-02-09 | 2025-04-02 | Immatics US, Inc. | Methods for manufacturing t cells |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| CN110531077B (zh) * | 2018-05-25 | 2023-07-07 | 荣昌生物制药(烟台)股份有限公司 | 间皮素免疫组化检测试剂盒 |
| WO2020028562A1 (en) * | 2018-07-31 | 2020-02-06 | Loma Linda University | Snail sirna-loaded mesoporous silica nanoparticles |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (de) * | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| MX2021015033A (es) | 2019-06-06 | 2022-01-18 | Immatics Biotechnologies Gmbh | Clasificacion con contraseleccion utilizando peptidos de secuencias similares. |
| CN118666956A (zh) * | 2019-06-25 | 2024-09-20 | 蒙特利尔大学 | 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CA3150197A1 (en) * | 2019-08-09 | 2021-02-18 | Immatics US, Inc. | Methods for peptide mass spectrometry fragmentation prediction |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| EP4165059A1 (en) * | 2020-06-13 | 2023-04-19 | Complete Omics Inc. | Method and system for neoantigen analysis |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| KR20230135589A (ko) | 2020-12-31 | 2023-09-25 | 이매틱스 유에스 인코포레이티드 | Cd8 폴리펩타이드, 조성물 및 이의 사용 방법 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4326858A4 (en) * | 2021-04-23 | 2025-03-12 | VLP Therapeutics, Inc. | GALECTIN-TARGETED IMMUNOTHERAPY |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| CN113241177B (zh) * | 2021-05-19 | 2024-05-10 | 上海宝藤生物医药科技股份有限公司 | 一种评估免疫力水平的方法、装置、设备及存储介质 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN114657158B (zh) * | 2022-05-25 | 2022-10-21 | 深圳吉诺因生物科技有限公司 | Ido1相关疫苗及其应用 |
| GB202302709D0 (en) * | 2023-02-24 | 2023-04-12 | Genome Res Ltd | Method of identifying t cell recpetors of interest |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1575500A4 (en) * | 2002-07-12 | 2007-01-03 | Univ Johns Hopkins | MESOTHELIN VACCINE AND MODEL SYSTEMS |
| WO2004050860A2 (en) * | 2002-12-04 | 2004-06-17 | Diadexus, Inc. | Compositions, splice variants and methods relating to colon specific genes and proteins |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| CA2579558A1 (en) * | 2004-09-08 | 2006-03-16 | Ludwig Institute For Cancer Research | Cancer-testis antigens |
| WO2006106912A1 (ja) * | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 癌関連抗原アナログペプチド、およびその利用 |
| ES2341802T3 (es) | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| PL1760089T3 (pl) | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| CA2665568C (en) * | 2006-10-04 | 2018-01-09 | Janssen Pharmaceutica, N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
| US8097242B2 (en) | 2006-10-05 | 2012-01-17 | The Board Of Trustees Of The University Of Arkansas | Target CA125 peptides for cancer immunotherapy |
| PL2565204T3 (pl) * | 2007-07-27 | 2016-03-31 | Immatics Biotechnologies Gmbh | Nowe immunogenne epitopy do immunoterapii |
| BRPI0813621A2 (pt) * | 2007-07-27 | 2017-05-09 | Immatics Biotechnologies Gmbh | imunoterapia contra tumores neuronais e cerebrais |
| US20100260764A1 (en) * | 2007-08-29 | 2010-10-14 | Marinkovich M Peter | Compositions and methods for inhibiting squamous cell carcinoma |
| SI2119726T2 (en) * | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | New and powerful Class II MHC peptides derived from survivin and neurocane |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| WO2014011465A2 (en) * | 2012-07-13 | 2014-01-16 | Albert Einstein College Of Medicine Of Yeshiva University | Aptamer-targeted antigen delivery |
| MY171854A (en) * | 2013-03-29 | 2019-11-05 | Sumitomo Dainippon Pharma Co Ltd | Wt1 antigen peptide conjugate vaccine |
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| ES2983924T3 (es) * | 2015-03-27 | 2024-10-28 | Immatics Biotechnologies Gmbh | Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
-
2015
- 2015-07-15 GB GBGB1512369.8A patent/GB201512369D0/en not_active Ceased
- 2015-07-15 MY MYPI2018700111A patent/MY189596A/en unknown
-
2016
- 2016-07-14 IL IL308200A patent/IL308200A/en unknown
- 2016-07-14 BR BR112017028558-4A patent/BR112017028558A2/pt not_active Application Discontinuation
- 2016-07-14 AU AU2016293047A patent/AU2016293047B9/en not_active Ceased
- 2016-07-14 MX MX2018000543A patent/MX2018000543A/es unknown
- 2016-07-14 BR BR122023024959-3A patent/BR122023024959A2/pt unknown
- 2016-07-14 SG SG10202100291XA patent/SG10202100291XA/en unknown
- 2016-07-14 HU HUE16739102A patent/HUE049937T2/hu unknown
- 2016-07-14 WO PCT/EP2016/066706 patent/WO2017009400A1/en not_active Ceased
- 2016-07-14 PE PE2018000052A patent/PE20180693A1/es unknown
- 2016-07-14 SG SG10202100298SA patent/SG10202100298SA/en unknown
- 2016-07-14 SG SG10202100294WA patent/SG10202100294WA/en unknown
- 2016-07-14 EA EA201890027A patent/EA201890027A1/ru unknown
- 2016-07-14 CR CR20200409A patent/CR20200409A/es unknown
- 2016-07-14 PT PT167391028T patent/PT3322717T/pt unknown
- 2016-07-14 KR KR1020227017673A patent/KR20220075451A/ko not_active Ceased
- 2016-07-14 DK DK16739102.8T patent/DK3322717T3/da active
- 2016-07-14 CR CR20200408A patent/CR20200408A/es unknown
- 2016-07-14 CN CN202111534523.0A patent/CN114163501A/zh active Pending
- 2016-07-14 CN CN201680041146.8A patent/CN107922469A/zh active Pending
- 2016-07-14 PL PL16739102T patent/PL3322717T3/pl unknown
- 2016-07-14 UA UAA201712985A patent/UA124875C2/uk unknown
- 2016-07-14 NZ NZ739128A patent/NZ739128A/en not_active IP Right Cessation
- 2016-07-14 HR HRP20201281TT patent/HRP20201281T1/hr unknown
- 2016-07-14 LT LTEP16739102.8T patent/LT3322717T/lt unknown
- 2016-07-14 PE PE2023001339A patent/PE20240645A1/es unknown
- 2016-07-14 EP EP20170212.3A patent/EP3705491A1/en active Pending
- 2016-07-14 MA MA42441A patent/MA42441B1/fr unknown
- 2016-07-14 IL IL292131A patent/IL292131A/en unknown
- 2016-07-14 MA MA41717A patent/MA41717A1/fr unknown
- 2016-07-14 SG SG10202100297QA patent/SG10202100297QA/en unknown
- 2016-07-14 EP EP16739102.8A patent/EP3322717B1/en active Active
- 2016-07-14 SG SG10202100295RA patent/SG10202100295RA/en unknown
- 2016-07-14 JP JP2018501316A patent/JP6862411B2/ja not_active Expired - Fee Related
- 2016-07-14 CA CA2992506A patent/CA2992506A1/en active Pending
- 2016-07-14 ME MEP-2020-159A patent/ME03808B/me unknown
- 2016-07-14 SG SG10202100296PA patent/SG10202100296PA/en unknown
- 2016-07-14 ES ES16739102T patent/ES2807832T3/es active Active
- 2016-07-14 US US15/209,845 patent/US9889159B2/en not_active Expired - Fee Related
- 2016-07-14 CA CA3221097A patent/CA3221097A1/en active Pending
- 2016-07-14 SG SG10202100292VA patent/SG10202100292VA/en unknown
- 2016-07-14 MD MDE20180524T patent/MD3322717T2/ro not_active IP Right Cessation
- 2016-07-14 SI SI201630868T patent/SI3322717T1/sl unknown
- 2016-07-14 MA MA050542A patent/MA50542A/fr unknown
- 2016-07-14 CR CR20180027A patent/CR20180027A/es unknown
- 2016-07-14 CR CR20200410A patent/CR20200410A/es unknown
- 2016-07-14 KR KR1020187000652A patent/KR20180030506A/ko not_active Ceased
- 2016-07-14 RS RS20200937A patent/RS60647B1/sr unknown
-
2017
- 2017-11-15 US US15/813,610 patent/US10463696B2/en active Active
-
2018
- 2018-01-02 IL IL256697A patent/IL256697B/en unknown
- 2018-01-03 PH PH12018500005A patent/PH12018500005A1/en unknown
- 2018-01-08 ZA ZA2018/00129A patent/ZA201800129B/en unknown
- 2018-01-12 MX MX2023014146A patent/MX2023014146A/es unknown
- 2018-01-12 CO CONC2018/0000252A patent/CO2018000252A2/es unknown
- 2018-01-15 CL CL2018000124A patent/CL2018000124A1/es unknown
-
2019
- 2019-08-30 US US16/556,695 patent/US10568909B2/en active Active
- 2019-08-30 US US16/556,704 patent/US10639332B2/en active Active
- 2019-08-30 US US16/556,549 patent/US10639331B2/en active Active
- 2019-11-19 CL CL2019003312A patent/CL2019003312A1/es unknown
- 2019-11-19 CL CL2019003311A patent/CL2019003311A1/es unknown
- 2019-11-19 CL CL2019003313A patent/CL2019003313A1/es unknown
- 2019-11-19 CL CL2019003310A patent/CL2019003310A1/es unknown
-
2020
- 2020-01-31 US US16/777,919 patent/US10722538B2/en active Active
- 2020-03-24 JP JP2020052558A patent/JP7074367B2/ja not_active Expired - Fee Related
- 2020-03-30 JP JP2020059702A patent/JP7239992B2/ja active Active
- 2020-04-06 JP JP2020068264A patent/JP7074369B2/ja not_active Expired - Fee Related
- 2020-04-13 JP JP2020071602A patent/JP7074370B2/ja not_active Expired - Fee Related
- 2020-04-20 JP JP2020074570A patent/JP7239993B2/ja active Active
- 2020-04-27 JP JP2020078116A patent/JP2020182458A/ja active Pending
- 2020-05-11 JP JP2020082964A patent/JP2020198875A/ja active Pending
- 2020-05-18 JP JP2020086514A patent/JP7205919B2/ja active Active
- 2020-05-25 JP JP2020090207A patent/JP2021000078A/ja active Pending
- 2020-06-15 AU AU2020203971A patent/AU2020203971B2/en not_active Ceased
- 2020-06-18 US US16/905,550 patent/US10888587B2/en not_active Expired - Fee Related
- 2020-06-18 US US16/905,530 patent/US10881690B2/en active Active
- 2020-06-18 US US16/905,499 patent/US10869897B2/en active Active
- 2020-09-08 CY CY20201100848T patent/CY1123505T1/el unknown
- 2020-10-13 AU AU2020256318A patent/AU2020256318A1/en not_active Abandoned
- 2020-12-09 US US17/116,635 patent/US11071756B2/en not_active Expired - Fee Related
- 2020-12-16 US US17/123,585 patent/US20210106624A1/en not_active Abandoned
-
2021
- 2021-04-30 US US17/245,076 patent/US11278571B2/en not_active Expired - Fee Related
- 2021-04-30 US US17/245,133 patent/US11819518B2/en active Active
- 2021-04-30 US US17/245,012 patent/US20210252064A1/en not_active Abandoned
- 2021-04-30 US US17/245,031 patent/US11806366B2/en active Active
- 2021-04-30 US US17/245,105 patent/US11246889B2/en not_active Expired - Fee Related
-
2022
- 2022-02-04 AU AU2022200745A patent/AU2022200745B2/en not_active Ceased
- 2022-10-17 US US18/047,236 patent/US20230241107A1/en not_active Abandoned
- 2022-10-17 US US18/047,234 patent/US20230241106A1/en not_active Abandoned
- 2022-10-17 US US18/047,195 patent/US20230190813A1/en not_active Abandoned
- 2022-10-21 US US18/048,489 patent/US20230285458A1/en not_active Abandoned
- 2022-10-21 US US18/048,796 patent/US20230201259A1/en not_active Abandoned
- 2022-10-24 US US18/049,105 patent/US20230086100A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020198875A5 (2) | ||
| JP2020182458A5 (2) | ||
| JP2020191862A5 (2) | ||
| JP2021101700A5 (2) | ||
| JP2024041841A5 (2) | ||
| JP2019513005A5 (2) | ||
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| JP2020516681A5 (2) | ||
| JP2024099580A5 (2) | ||
| HRP20201281T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma | |
| HRP20210709T1 (hr) | Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma | |
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| JP2019536426A5 (2) | ||
| JP2019515650A5 (2) | ||
| JP2019502360A5 (2) | ||
| JP2021535900A5 (2) | ||
| JP2018510628A5 (2) | ||
| JP2019511214A5 (2) | ||
| JP2018529320A5 (2) | ||
| JP2020506690A5 (2) | ||
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2010527919A5 (2) | ||
| JP2019515653A5 (2) | ||
| JP2021528046A5 (2) | ||
| JP2019520038A5 (2) |